Paulina Zydowicz-Machtel
Preclinical Specialist JJP Biologics
Paulina Zydowicz Machtel, PhD, is a researcher with over ten years of experience in developing strategies to regulate gene expression in disease models. Her work focuses on molecular mechanisms driving cancer development, supported by strong expertise in advanced molecular biology techniques. Paulina has led multiple research projects, supervised students, and presented her work internationally. She is a co author of seven scientific publications and is deeply engaged in scientific writing and data analysis. Passionate about translational research and science communication, she is driven by the goal of transforming complex biological insights into innovative therapies that can improve patient outcomes.
Seminars
Tuesday 5th May 2026
Spotlighting Preclinical Modelling to Validate JJP‑1008 as a First‑in‑Class Anti‑CD270 Checkpoint Inhibitor
3:00 pm
- Revealing CD270 as a key melanoma escape mechanism through tumour‑model–driven studies demonstrating that high CD270 expression is mutually exclusive with PD‑L1 and strongly associated with resistance to PD‑1/PD‑L1 inhibitors
- Demonstrating robust immunostimulatory activity of JJP‑1008 in in vitro models and humanized melanoma models (CDX/NOG), where repeated dosing inhibited aggressive tumour growth, reduced cachexia, and increased CD4⁺/CD8⁺ T‑cell infiltration—shifting the microenvironment from immunosuppression to activation
- Elucidating JJP‑1008’s selective blockade of immunosuppressive HVEM signals (BTLA/CD160) while preserving LIGHT‑mediated co‑stimulation, offering a novel mechanism to restore antitumour immunity and enhance model‑based evaluation of next‑generation immunotherapies
